Ken Griffin Diffusion Pharmaceuticals Inc. Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
BUY
$4.15 - $6.6 $77,426 - $123,136
18,657 New
18,657 $77,000

Others Institutions Holding DFFN

# of Institutions
2
Shares Held
49
Call Options Held
0
Put Options Held
0
View Full List

About Diffusion Pharmaceuticals Inc.

DFFN Quotes by TradingView
  • Ticker DFFN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,039,120
  • Market Cap $18.9M
  • Description
  • Diffusion Pharmaceuticals Inc., a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc. was founded in 2001 a...
More about DFFN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email